Review ArticleReviewsR
Clinical Factors Associated with Treatment Outcomes Following Whole-brain Irradiation in Patients with Prostate Cancer
LIESA DZIGGEL, STEVEN E. SCHILD, THEO VENINGA, AMIRA BAJROVIC and DIRK RADES
In Vivo January 2017, 31 (1) 35-38;
LIESA DZIGGEL
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
STEVEN E. SCHILD
2Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
THEO VENINGA
3Department of Radiotherapy, Dr. Bernard Verbeeten Institute, Tilburg, the Netherlands
AMIRA BAJROVIC
4Department of Radiotherapy, University Medical Center Eppendorf, Hamburg, Germany
DIRK RADES
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
In this issue
In Vivo
Vol. 31, Issue 1
January-February 2017
Clinical Factors Associated with Treatment Outcomes Following Whole-brain Irradiation in Patients with Prostate Cancer
LIESA DZIGGEL, STEVEN E. SCHILD, THEO VENINGA, AMIRA BAJROVIC, DIRK RADES
In Vivo Jan 2017, 31 (1) 35-38;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer
- Prognostic Role of Pre-Treatment Symptoms for Survival of Patients Irradiated for Brain Metastases
- Diagnosis-specific WBRT-30-CRC Score for Estimating Survival of Patients Irradiated for Brain Metastases from Colorectal Cancer
- Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses
- Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM
- Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Does the Interval Between Imaging and Treatment Matter?
- Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer
- Contribution of Patient-reported Symptoms Before Palliative Radiotherapy to Development of Multivariable Prognostic Models
- Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases